Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia

  1. Lookup NU author(s)
  2. Dr Lisa Russell
  3. Lisa Jones
  4. Dr Amir Enshaei
  5. Dr Stefano Tonin
  6. Sarra Ryan
  7. Dr Jeyanthy Eswaran
  8. Dr Sirintra Nakjang
  9. Professor Anthony Moorman
  10. Professor Christine Harrison
Author(s)Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ
Publication type Article
JournalGenes, Chromosomes & Cancer
Year2016
Volume56
Issue5
Pages363-372
ISSN (print)1045-2257
ISSN (electronic)1098-2264
Full text is available for this publication:
Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5-15% of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We aimed to determine the clinical and genetic landscape of those with IGH-CRLF2 or P2RY8-CRLF2 (CRLF2-r) using multiple genomic approaches. Clinical and demographic features of CRLF2-r patients were characteristic of B-ALL. Patients with IGH-CRLF2 were older (14yrs v 4yrs, P<0.001), while the incidence of CRLF2-r among Down syndrome patients was high (50/161, 31%). CRLF2-r co-occurred with primary chromosomal rearrangements but the majority (111/161, 69%) had B-other ALL. Copy number alteration (CNA) profiles were similar to B-other ALL, although CRLF2-r patients harboured higher frequencies of IKZF1 (60/138, 43% v 77/1351, 24%) and BTG1 deletions (20/138, 15% v 3/1351, 1%). There were significant differences in CNA profiles between IGH-CRLF2 and P2RY8-CRLF2 patients: IKZF1 (25/35, 71% v 36/108, 33%, P<0.001), BTG1 (11/35, 31% v 10/108, 9%, P =0.004) and ADD3 deletions (9/19, 47% v 5/38, 13%, P =0.008). A novel gene fusion, USP9X-DDX3X, was discovered in 10/54 (19%) of patients. Pathway analysis of the mutational profile revealed novel involvement for focal adhesion. Although the functional relevance of many of these abnormalities are unknown, they likely activate additional pathways, which may represent novel therapeutic targets.
PublisherJohn Wiley & Sons
URLhttp://dx.doi.org/10.1002/gcc.22439
DOI10.1002/gcc.22439
PubMed id28033648
Actions    Link to this publication

Altmetrics provided by Altmetric

Share